help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brown, M. R.
Right arrow Articles by Baird, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, M. R.
Right arrow Articles by Baird, A.

Endocrinology, Vol 129, 2355-2360, Copyright © 1991 by Endocrine Society

ARTICLES

Transforming growth factor-beta: role in mediating serum-induced endothelin production by vascular endothelial cells

MR Brown, J Vaughan, LL Jimenez, W Vale and A Baird
Department of Medicine, University of California, San Diego, La Jolla 92093-0817.

Studies were performed to characterize the identity of the factors present in calf serum that stimulate endothelin (ET) production by vascular endothelial cells in culture. Two putative candidates responsible for the ET-releasing activity present in serum are members of the transforming growth factor-beta (TGF beta) superfamily, TGF beta 1 and activin A. TGF beta 1 antiserum was used to block the actions of TGF beta 1, and follistatin was used to block the actions of activin. Treatment of serum with TGF beta 1 antiserum attenuates ET production by vascular endothelial cells. TGF beta 1 antiserum (1 microliters) completely prevents the release of ET produced by 0.1% and 0.3% serum. Follistatin is a potent inhibitor of activin-induced ET release but does not alter serum-induced ET production. Because serum-induced ET release is dependent on TGF beta, it may be a physiological regulator of ET production by vascular endothelial cells.


This article has been cited by other articles:


Home page
 IOVSHome page
Z. A. Khan, M. Cukiernik, J. R. Gonder, and S. Chakrabarti
Oncofetal Fibronectin in Diabetic Retinopathy
Invest. Ophthalmol. Vis. Sci., January 1, 2004; 45(1): 287 - 295.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
J. A. Keelan, R. Taylor, J.-C. Schellenberg, N. P. Groome, M. D. Mitchell, and R. A. North
Serum Activin A, Inhibin A, and Follistatin Concentrations in Preeclampsia or Small for Gestational Age Pregnancies
Obstet. Gynecol., February 1, 2002; 99(2): 267 - 274.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
T Bodamyali, C R Stevens, M E J Billingham, S Ohta, and D R Blake
Influence of hypoxia in inflammatory synovitis
Ann Rheum Dis, December 1, 1998; 57(12): 703 - 710.
[Full Text]

Home page
 CirculationHome page
K. Okada, Y. Nishida, H. Murakami, I. Sugimoto, H. Kosaka, H. Morita, C. Yamashita, and M. Okada
Role of Endogenous Endothelin in the Development of Graft Arteriosclerosis in Rat Cardiac Allografts : Antiproliferative Effects of Bosentan, a Nonselective Endothelin Receptor Antagonist
Circulation, June 16, 1998; 97(23): 2346 - 2351.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1991 by The Endocrine Society